Date Title Description PDF
23 Feb 2022 On business and financial situation The Company releases the press release related to the full year 2021 financial results Download
23 Feb 2022 On business and financial situation The Company releases the full year 2021 financial results presentation Download
23 Feb 2022 About corporate governance The Company informs about the agreements adopted by the Board of Directors  Download
22 Feb 2022 On buy-back programmes ROVI reports the end of the share buy-back programme, effective as of 3 November 2021, and the launching of a new share buy-back programme, effective as of 23 February 2022.     Download
16 Feb 2022 On business and financial situation Moderna and ROVI announced that they expand their long-term collaboration for the manufacture of mRNA medicines over the next ten years       Download

Pages

Date Title Description PDF
08 Jul 2024 Other relevant information The Company informs about the dividends payment.   Download
04 Jul 2024 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the second quarter of 2024 Download
24 Jun 2024 Announcement of General Shareholders' Meeting The Company reports on the resolutions adopted by the Ordinary General Shareholders' Meeting and by the Board of Directors. Download
11 Jun 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 7 June 2024 and 11 June 2024 and end of the share buyback program Download
07 Jun 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 31 May and 6 June 2024 Download

Pages

Date Title Description PDF
05 Oct 2017 Contratos de liquidez y contrapartida Liquidity contract: modification of transactions conducted from 11 July to 30 September 2017. Download
03 Oct 2017 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted from 11 July to 30 September 2017   Download
07 Sep 2017 Otros sobre negocio y situación financiera The Company informs that commences the enoxaparin biosimilar marketing in Germany Download
26 Jul 2017 Información sobre resultados ROVI releases the presentation related to the 2017 first half results Download
26 Jul 2017 Información sobre resultados ROVI releases the presentation related to the 2017 first half results Download

Pages